AllSci News
Spot Biosystems emerges from stealth with USD 40 million, early human data for non-viral dystrophin delivery
Palo Alto-based Spot Biosystems has emerged from stealth with USD 40 million in venture financing and early clinical data suggesting its extracellular...
Legend Bio raises USD 226 million to fund pipeline as CARVYKTI sales accelerate toward 2026 profitability
Bridgewater, New Jersey-based Legend Biotech Corporation (Nasdaq: LEGN) announced the pricing of an underwritten public offering of American Depositary...
LG Chem bets on AI-designed antibodies to solve solid tumor toxicity problem
South Korea-based LG Chem (KRX: 051910) has agreed to fund discovery of a tumour-selective multispecific antibody through UK-based LabGenius Therapeutics,...
D&D Pharmatech pairs oral peptide platform with LG's generative AI to accelerate drug discovery
D&D Pharmatech (KOSDAQ: 347850), whose oral peptide delivery platform has attracted over USD 7 billion in downstream pharma acquisitions, has signed a...
Biogen accelerates immunology pivot with USD 1 billion RayThera acquisition
Biogen (Nasdaq: BIIB) has agreed to acquire San Diego-based RayThera Inc. for up to USD 1 billion, adding a portfolio of small molecule anti-inflammatory...
Kardigan prices up IPO for at least USD 400m on cardiac myosin inhibitor pedigree
Kardigan, Inc. (Nasdaq: KARD), a clinical-stage precision cardiovascular company whose three in-licensed drug candidates target indications with no approved...
AB Science secures US patent for kinase inhibitor masitinib in metastatic prostate cancer
France-based AB Science (Euronext Paris: AB) received a formal grant from the US Patent and Trademark Office for US patent 12,648,944, covering…
GSK, Spero get FDA nod for first oral carbapenem in resistant UTIs
The US FDA approved Utebzi (tebipenem pivoxil) for complicated urinary tract infections (cUTIs), including pyelonephritis, in adults with limited or no alternative…
F2G, Shionogi's oral anti-fungal scores Phase III success against Gilead's AmBisome in invasive aspergillosis
Olorofim's Phase III non-inferiority win against Gilead's AmBisome (liposomal amphotericin B) in azole-refractory invasive aspergillosis reported by...
Roche files Lunsumio Velo plus Polivy for approval as first bispecific-ADC combo against lymphoma
The US FDA's acceptance of a supplemental Biologics License Application for Lunsumio Velo (mosunetuzumab) in combination with Polivy (polatuzumab vedotin)...
FDA backs uniQure's three-year data package for AMT-130 accelerated approval filing
uniQure N.V. (Nasdaq: QURE) has announced plans to submit a Biologics License Application (BLA) to the US FDA seeking accelerated approval of AMT-130 for...
Jazz bets USD 56m on AbCellera's T-cell engagers for solid tumors
Jazz Pharmaceuticals (Nasdaq: JAZZ) has committed USD 56 million upfront to access AbCellera Biologics' (Nasdaq: ABCL) T-cell engaging multispecific...
Gero raises USD 17m to advance AI-driven aging drug discovery platform
Singapore-based Gero, a physics-first AI drug discovery company focused on age-related disease, has announced USD 17 million in new equity financing,...
Oligomerix picks up NIH grant to push oral tau inhibitor into clinic for Alzheimer's
Oligomerix, a clinical-stage biotechnology company based at the Albert Einstein College of Medicine in the Bronx, New York, has received a USD 1.9 million...
MultiValent launches with USD 27.4m to advance dual-target prostate cancer conjugate into clinic
Los Altos, California-based MultiValent Biotherapies, Inc. has closed a USD 27.425 million first closing of its Series A Preferred Stock financing to...
The AllSci Brief
Free, systematic R&D and deal news. Daily.